Agios Pharma (AGIO) Misses Q2 EPS by 22c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Agios Pharma (AGIO) PT Raised to $83 at Oppenheimer on 2Q Report; 'Strong Clinical Update'
August 8, 2017 11:20 AM EDTOppenheimer raised its price target on Agios Pharma (NASDAQ: AGIO) to $83.00 (from $75.00) while maintaining a Outperform rating, following the company's second quarter earnings report.
Analyst Leah Cann notes the company delivered second quarter earnings per share results below expectations from higher research & development... More
